Tuesday, December 5, 2023
September 19 - 21, 2020; Virtual Meeting
ESMO 2020
Surveillance After CRC Resection Does Not Improve Survival
ESMO 2020
Chemoradiation Boosts Glioblastoma Survival in Real-World Setting
ESMO 2020
Clinical Factors and Treatment Tied to COVID-19 Mortality
ESMO 2020
Divergent Findings With Paclitaxel and Nab-Paclitaxel in TNBC
ESMO 2020
Pembrolizumab Shows Activity in Select Rare Sarcomas
ESMO 2020
New Drug for Prostate Cancer: Ipatasertib, an AKT Inhibitor
ESMO 2020
Lorlatinib: Another First-Line Option for ALK-Positive NSCLC?
ESMO 2020
'Paradigm Shift' in Gastric Junction Cancers With Nivolumab
ESMO 2020
A Glimmer of Hope for Immunotherapy in SCLC?
ESMO 2020
New First-Line Standard of Care for Esophageal Cancer?
ESMO 2020
Not All Prostate Cancer Mutations Created Equal for Olaparib
ESMO 2020
Survey Quantifies COVID-19's Impact on Oncology
ESMO 2020
Abemaciclib Cuts Early Recurrence in High-risk Breast Cancer
ESMO 2020
Lenvatinib Combo May Offer Hope After Immunotherapy in Melanoma
ESMO 2020
Sotorasib Is a 'Triumph of Drug Discovery' in Cancer
ESMO 2020
First-in-Class ADC Ups Survival in mTNBC
ESMO 2020
Nivo-Cabo Combo Joins Advanced RCC Treatment Ranks
ESMO 2020
Oncologist Distress and Burnout Has Increased During COVID
ESMO 2020
The March of Immunotherapy Continues at ESMO 2020
Medscape Oncology© WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
ctDNA Shows Promise for Assessing Lung Cancer Treatment Response
Osimertinib as Adjuvant Therapy in
EGFR-Mutant Lung Cancer
Highlights in Ovarian Cancer From ESMO 2020
Renal Cell Carcinoma Highlights From ESMO 2020
Prostate Cancer Highlights From ESMO 2020
Breakthroughs in Melanoma From ESMO Virtual Congress 2020
David Kerr on ESMO's Most Important Colorectal Cancer Trials
An Important Negative Study for Post-op RT in Lung Cancer
CDK4/6 Inhibitors in Early Breast Cancer: Different Trial Results Means Good Science
Innate Immune Response Produces 'Phenomenal' Breast Cancer Control
ESMO: How Cancer Services Were Hit by COVID-19 First Wave
For Immunotherapy in TNBC, Nab-paclitaxel Is a Must
ESMO: STIMULI Optimism Despite Trial Data Disappointment
ESMO: monarchE Abemaciclib 'Landmark' HR+ Breast Cancer Study
Burnout and Distress: ESMO Hears How COVID-19 Impacted Oncologists
